Archive for the ‘Press Releases’ Category
Kineta, Universities of Washington and Texas Win $8.1M for Antiviral Biodefense Drugs
Last Updated on Tuesday, 8 May 2012 10:54 Written by Editor Tuesday, 8 May 2012 10:54
A collaboration between Kineta, the University of Washington, and the University of Texas Medical Branch has been awarded $8.1 million in funding by the National Institute of Allergy and Infectious Diseases (NIAID) to develop antiviral drugs against potential biothreat agents as Ebola, plague, and Japanese encephalitis.
Researchers at the University of Washington’s NIH-sponsored Center for the Study of Immune Mechanisms of Virus Control have been working to understanding the basis of the body’s innate immunity to virus infection and the intracellular processes and virus-host interactions that control viral replication. The program will build on existing collaborations between Kineta and the University of Washington, including ongoing NIAID-funded research to develop antiviral drugs and vaccine adjuvants.
As part of the latest NIAID partnership, Kineta will lead drug optimization and in vivo pharmacology work, and scientists at the University of Washington will provide additional bioinformatics and systems biology genomics analysis. Collaborators at the University of Texas Medical Branch’s Galveston National Laboratory will oversee research on biosafety level 4 viral agents, including Ebola and Nipah viruses.
“This award enables us to push further and work with more high-priority viruses,” comments University of Washington professor Michael Gale Jr., Ph.D., principal grant investigator. “These diseases are major concerns of the U.S. government for their risk of sparking a pandemic and their potential use as bioterrorist weapons. By utilizing an innate immune pathway we hope to develop better drugs that won’t be outsmarted by viral mutation.”
Established in 2007, Kineta is developing drugs that act at the level of the innate and adaptive immune systems to treat infectious diseases and autoimmune disorders. Its primary target is retinoic acid inducible gene I protein (RIG-1), a key element of the innate immune system. Kineta says it has identified compounds that can influence RIG-1 and trigger natural anti-infection immune responses. The aim is to develop broad-based antiviral products against a range of infectious diseases such as HIV, hepatitis C, influenza, and West Nile Virus, and also exploit the RIG-1 platform to generate vaccine adjuvants.
Source: http://www.genengnews.com/
Posted under BioInformatics, North America, Press Releases, R & D, Research Projects | No Comments
Transcriptional Diversity Found in Circulating Tumor Cells from Individual Breast Cancer Patients
Last Updated on Tuesday, 8 May 2012 10:44 Written by Editor Tuesday, 8 May 2012 10:44
Scientists have shown that there is considerable transcriptional diversity between individual circulating tumor cells (CTCs) found in the blood of a single cancer patient, indicating that multiple treatments may be required to adequately kill off a patient’s cancer. Researchers led by a team at Stanford University used an immunomagnetic enrichment device technique known as MagSweeper to isolate CTCs from blood samples taken from breast cancer patients. The investigators then used microfluidic-based single-cell transcriptional profiling to look at the expression of 87 cancer-associated and reference genes in individual CTCs.
The results, reported in PLoS One, showed that there was significant heterogeneity in the transcription profiles of CTCs released into the blood, even among those from a single patient. Importantly, the expression profiles of all CTCs were very different from those of seven different primary and metastatic human breast cancer cell lines that are widely used for drug discovery and in vitro drug testing. “Our finding suggests that perhaps they’re not that helpful as models of spreading cancers,” claims lead investigator Stefanie S. Jeffrey, M.D., professor of surgery and chief of surgical oncology research at Stanford’s Department of Surgery.
The researchers describe their findings in a paper titled “Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines.”
The treatment of metastatic cancer is determined largely by biomarkers from the primary tumor, despite the fact that metastatic tumors and primary tumors may be very different. Given that metastases are seeded at distal sites by CTCs released into the bloodstream, a method for accurately profiling such cells could provide valuable information for guiding therapy, the authors note. However, accurate characterization of CTCs is hampered both due to contamination with white blood cells and the limited sensitivity of analytical methods, which means analyses may have to carried out on pooled CTCs.
To demonstrate that single-cell transcription profiling is possible for CTCs, the team used the MagSweeper enrichment technology to isolate CTCs from breast cancer patient blood samples, and then applied microfluidic-based single-cell transcriptional profiling technique to determine the expression levels of 87 genes in individual CTCs. Blood samples were taken from 20 breast cancer patients with primary tumors, and 30 patients with metastatic disease. Of the 87 genes evaluated, 31 were consistently detected in at least 15% of the CTCs analyzed. Apart from three reference genes that were expressed in all the CTCs, the 28 remaining genes most commonly expressed were found to be relevant to nine basic functional categories: epithelial phenotype, epithelial mesenchymal transition, metastasis, PI3K/AKT/mTOR pathway, apoptosis, cell proliferation, DNA repair, cell metabolism, and stem cell phenotype.
Clustering analyses indicated that while the transcription profiles of CTCs varied considerably, they fell into two broad groups, both of which could be present in the same patient. Cluster I represented a relatively small proportion of the CTCs which, in comparison with cluster II, were characterized by stronger expression of S100A9, CD24, VIM, CXCR4, MAPK14, AKT2, PIK3R1, CTNNB1, CD44, and ZEB2. Importantly, both clusters robustly expressed a number of metastasis-associated genes.
Of particular note was the finding that the CTCs were almost exclusively triple negative (i.e., lacking Er, PR, and Her2 expression), irrespective of whether the patient’s primary tumor was triple negative or not. “Loss of expression of Er/PR/Her2 in CTCs noted in our particular patient sample could explain why therapies that target these biomarkers may fail to control end-stage disease,” professor Jeffrey et al point out.
And surprisingly, all the CTC transcription profiles differed greatly from those of three commonly used primary and four metastatic human breast cancer cell lines. “Overall, expression patterns of <10% (2/28) common tumor-associated gene profiles of CTCs were recapitulated by a subset of tumor cell line models,” the investigators write.
“Although CTC heterogeneity between patients is well recognized, an important finding in our study was that individual CTCs did not cluster by patient or disease stage (primary cancer vs. metastatic cancer), which again supports the concept that these cells belong to subpopulations with phenotypes fundamentally different from pooled tumor tissue,” they conclude. Studying and phenotyping the primary tumor alone may lead to suboptimal treatment selection … Our finding of CTC variability is consistent with primary and metastatic tumor heterogeneity and suggests that single cell phenotyping of CTCs is a practical approach to exploit this variability for the effective implementation of molecular guided cancer therapy on a more comprehensive scale than possible with mutational analysis of a few known genes.”
Source: http://www.genengnews.com/
Posted under North America, Press Releases, R & D, Research Projects, RNA Reasearch | No Comments
Islet Licenses Yale IP to Identify Beta Cell Death Before Diabetes Manifests
Last Updated on Tuesday, 8 May 2012 10:41 Written by Editor Tuesday, 8 May 2012 10:41
Islet Sciences negotiated an exclusive license to a diagnostic technology developed at Yale University that it says can identify beta cell death and help diagnose diabetes well before clinical symptoms present. The IP is based on the detection of circulating hypomethylated B cell-derived DNA, as a biomarker of B cell destruction.
Islet Sciences is focused on the development of transplantation therapies for diabetes based on its porcine islet cell and polymer microencapsulation technologies. The firm’s initial product, Islet Sciences-P™, is being developed as a ready-to-use vialed suspension of microencapsulated porcine islet cells for injection into the abdominal cavity.
In April Islet acquired DiaKine Therapeutics, which is developing a pipeline of treatments for diabetes. DiaKine’s most advanced product, Lisofylline, is in Phase II development as an intravenously administered adjunct therapy to islet cell transplantation. The drug is designed to improve the function of insulin-producing islet cells and protect them from damage and premature death associated with type 1 diabetes. A subcutaneous formulation of Lisofylline is in addition being evaluated in a Phase I study in newly diagnosed type 1 diabetes patients.
DiaKine’s preclinical pipeline includes a range of orally bioavailable immune modulators, including candidates for the treatment of latent autoimmune diabetes in adults and insulin-dependent type 2 diabetes, and diabetic nephropathy and retinopathy. Last month DiaKine received two separate grants from the NIH ($1.83 million) and Iacocca Foundation ($250,000).
Source: http://www.genengnews.com/
Posted under North America, Press Releases, R & D, Research Projects, RNA Reasearch | No Comments
Santen Nabs Japanese Co-Promotion Rights to Bayer and Regeneron’s Eylea
Last Updated on Tuesday, 8 May 2012 10:36 Written by Editor Tuesday, 8 May 2012 10:36
Santen Pharmaceuticals negotiated co-promotion rights to Regeneron Pharmaceuticals and Bayer HealthCare’s Eylea® (aflibercept; VEGF Trap-Eye) injection in Japan. Bayer’s Japanese subsidiary Bayer Yakuhin has already submitted a marketing application to the country’s regulatory authority for use of Eylea in the treatment of neovascular age-related macular degeneration (wet AMD). The deal with Santen means Bayer and Regeneron have in addition changed their previous 50/50 profit-share agreement for Eylea in Japan to a royalty-based deal.
Eylea was approved in the U.S. for the treatment of wet AMD in November 2011. Marketing authorization has also been granted in Australia, and applications in Europe and other markets have been submitted by Bayer. A Phase III wet AMD trial is ongoing in China. Phase III trials are also in progress to evaluate Eylea for the treatment of diabetic macular edema, myopic choroidal neovascularization, and branch retinal vein occlusion. Regeneron has filed an sBLA in the U.S. for Eylea in the treatment of central retinal vein occlusion.
Bayer and Regneron are collaborating on the global development of Eylea. Under terms of the deal, Regeneron retains all rights to the drug in the U.S., and Bayer HealthCare has marketing rights outside the U.S., where the companies will share profits from sales of Eylea equally (excluding Japan).
Eylea is a recombinant fusion protein comprising portions of human VEGF receptors 1 and 2 and extracellular domains fused to the Fc portion of IgG1. The product is formulated for intravitreal administration.
Source: http://www.genengnews.com/
Posted under Asia, North America, Press Releases, R & D | No Comments
Celgene Pays Epizyme $90M for Ex-U.S. Rights to Histone Methyltransferase Inhibitor
Last Updated on Monday, 7 May 2012 04:53 Written by Editor Monday, 7 May 2012 04:53
Celgene is paying Epizyme $90 million up front to established a partnership focused on the discovery, development, and commercialization of histone methyltransferase (HMT)-inhibiting drugs for genetically defined cancers. The up-front fee includes an equity investment in Epizyme and gives Celgene exclusive immediate ex-U.S. rights to its partner’s existing DOT1L HMT inhibitor program against mixed lineage leukemia (MLL).
Under terms of the deal Celgene also retains an exclusive option to license ex-U.S. rights to other Epizyme HMT inhibitor programs over an initial three-year period. Epizyme retains all U.S. rights to resulting products, and could earn up to another $160 million in milestones for each HMT inhibitor licensed by Celgene, and potentially double-digit royalties on ex-U.S. sales. The firms will work jointly to discover and develop HMT inhibitors, and will co-fund global development of collaborative programs.
Celgene’s expertise in epigenetic cancer therapies and Epizyme’s histone myethyltransferase platform are highly complementary, the partners claim. “Through this collaboration, Epizyme gains access to Celgene’s leading drug development resources, enabling us to substantially increase the breadth and depth of our efforts while retaining U.S. rights to our pipeline of personalized therapies,” comments Robert Gould, Ph.D., Epizyme CEO.
Epizyme is focused on the discovery and development of small molecule HMT inhibitors. The firm’s initial therapeutic target is MLL, a form of acute leukemia characterized by the presence of a chromosomal alteration (MLL-translocation) that recruits DOT1L activity to aberrant gene locations, leading to increased expression of specific gene products that drive leukemia cell proliferation. The small molecule DOT1L inhibitor is designed to selectively kill MLL cells, while sparing cells that don’t carry the MLL-translocation.
DOT1L is being developed in collaboration with the Leukemia and Lymphoma Society. Last month Eipzyme reported achieving a preclinical milestone in the program, and said it has to date received $2.6 million of potentially $7.5 million in funding under the partnership to support the DOT1L program through Phase I development.
The firm’s second lead program, EZH2, is in development in partnership with Eisai for the treatment of certain nonHodgkin lymphomas and breast cancer subtypes. The compound is designed to target the catalytic center of a multiprotein complex known as polycomb repressive complex 2 (PRC2). Epizyme and Eisai inked their deal for the EZH2 program back in March 2011.
Source: http://www.genengnews.com/gen-news-highlights/celgene-pays-epizyme-90m-for-ex-u-s-rights-to-histone-methyltransferase-inhibitor/81246684/
Posted under DNA Reasearch, North America, Press Releases, R & D, Research Projects | Comments Off
http://www.genengnews.com/gen-news-highlights/researchers-find-gene-key-to-maintaining-lung-cancer-stem-cells-promoting-tumor-initiation-and/81246678/
Last Updated on Monday, 7 May 2012 04:47 Written by Editor Monday, 7 May 2012 04:47
Scientists have identified a single gene that appears to be central to the maintenance of non-small cell lung cancer (NSCLC) cancer stem cells, as well as the initiation of tumor formation, growth and metastasis in vivo. A Mayo Clinic College of Medicine team found that cancer stem cells (CSCs) in oncosphere cultures demonstrated high expression levels of matrix metalloproteinase-10 (Mmp-10; or stromelysin 2), and that knocking down Mmp10 expression in these cells resulted in the loss of stem cell markers and the inhibition of oncosphere growth, clonal expansion, and tumor development. Mmp10-deficient oncospheres were in addition far less able to initiate tumor development than unmodified oncospheres when injected into experimental mice.
Reporting their findings in PLoS One, Alan P. Fields, M.D., and colleagues say subsequent analysis of gene expression data from human cancers highlighted a strong correlation between tumor Mmp10 expression and metastasis in a range of tumor types. “Our data demonstrate for the first time that Mmp10 is a critical lung cancer stem cell gene and novel therapeutic target for lung cancer stem cells,” they conclude. The investigators’ results are published in a paper titled “Matrix Metalloproteinase-10 Is Required for Lung Cancer Stem Cell Maintenance, Tumor Initiation and Metastatic Potential.”
MMPs have previously been implicated in lung tumor proliferation, invasion, and metastasis. The Mayo team’s own prior work suggested that Mmp10 is needed for transformed growth and invasion of human NSCLC cells in vitro, and mediates tumor initiation through the control of tumor-initiating bronchio-alveolar stem cell expansion.
Building on these findings the investigators have now looked more closely at the role of Mmp10 in the maintenance and tumorigenic potential of fully transformed mouse lung CSCs, a cell population characterized by stem-like properties including increased anchorage-independent growth in vitro, and enhanced tumor initiation, growth, and metastatic spread as orthotopic tumors in syngeneic mice.
The CSCs in these oncosphere cultures were found to express high levels of mRNAs for numerous genes associated with stem cell phenotype, and also high levels of Mmp10, but not other MMPs previously linked with lung cancer. The cultures in addition secreted much higher levels of Mmp10 protein into the medium in comparison with parental or redifferentiated cultures. As expected, oncosphere cultures demonstrated a loss of stem cell markers and Mmp10 expression when allowed to redifferentiate in adherent culture.
Notably, using an Mmp10-targeting RNAi to knock down Mmp10 mRNA expression in the oncosphere cultures led to an inhibition of transformed growth, loss of stem cell markers, and inhibition of clonal expansion, without impacting on cell viability. These effects could be restored by the addition of exogenous Mmp10.
Initial tests in vivo showed that while transplanting cells from oncosphere cultures into the lungs of syngeneic mice routinely led to the development of large tumors, cells from Mmp10-knockdown cultures generated fewer and small tumors, and also fewer metastases.
Importantly, the role of Mmp10 in tumorigenesis related to the gene’s expression by CSCs specifically, and not by other cells in the tumor environment. When the researchers injected unmodified oncospheres into Mmp10 knockout mice, tumor growth, size, and metastasis were equivalent to those resulting from the injection of unmodified oncospheres into wild-type syngeneic mice. This indicates that “Mmp10 expressed by oncospheres, but not from Mmp10 produced by other tumor-associated cells, is critical for tumor formation,” they write.
In a final set of analyses, the team analyzed publicly available gene-expression datasets of human tumors and found a strong positive correlation between Mmp10 expression and metastatic potential not only in human NSCLC, but also in colorectal cancer, melanoma, breast cancer, renal cell carcinoma, and prostate cancer.
The observation that Mmp10 appears to play a dual role in cancer, both in terms of maintaining the cancer stem cell population and facilitating metastasis, was an unexpected finding, the investigators note. Most other MMPs are expressed in the tumor microenvironment and cells and tissues surrounding the tumor, where they act to modify the tumor environment and facilitate cancer cell spread, Dr. Field explains. Conversely, “Mmp10 acts to keep these cancer stem cells healthy and self-renewing, which also helps explain why these cells escape conventional chemotherapy that might destroy the rest of the tumor.”
The team is now trying to define the mechanism by which Mmp10 stimulates the growth of cancer stem cells, and identify the design of inhibitors that block its activity. “Given the dual role in cancer stem cells and metastasis, targeting Mmp10 may be especially effective in treating these tumors,” he concludes.
Source: http://www.genengnews.com/gen-news-highlights/researchers-find-gene-key-to-maintaining-lung-cancer-stem-cells-promoting-tumor-initiation-and/81246678/
Posted under North America, Press Releases, R & D, Research Projects | Comments Off
Biotie Regains Asia-Pacific Rights for VAP-1 Antibody Program from Seikagaku
Last Updated on Monday, 7 May 2012 04:41 Written by Editor Monday, 7 May 2012 04:41
Biotie Therapies and Seikagaku have agreed to terminate their license agreement for Biotie’s VAP-1 antibody program, BTT-1023. The decision also nixes Seikagaky’s option for Biotie’s VAP-1 SSAO small molecule inhibitors.
Biotie had granted Seikagaku exclusive development and commercialization rights in Japan, Taiwan, Singapore, New Zealand, and Australia in April 2003, and the arrangement was built around Seikagaku’s expertise in locomotive diseases. “Based on recently generated exciting data in animal models, we have reprofiled the VAP-1 antibody program to primarily target fibrotic diseases, and this therapeutic focus is no longer aligned with Seikagaku’s business strategy,” explains Timo Veromaa, CEO of Biotie.
“Regaining the Asia-Pacific rights to BTT-1023 gives us the opportunity to build a fully global development strategy in the fibrosis disease area, which has a high level of unmet medical need,” Veromaa notes.
BTT-1023 is a fully human mAb that specifically binds to VAP-1. Biotie previously demonstrated encouraging efficacy and safety for BTT-1023 in early clinical studies in RA and psoriasis patients as well as in a range of preclinical models of inflammatory diseases including COPD plus certain neurological conditions.
More recently, Biotie generated data indicating that VAP-1 also has an important role in fibrotic diseases. This data, generated in part in collaboration with National Institute for Health Research Liver Biomedical Research Unit at the University of Birmingham, reveals significant potential for BTT-1023 in certain niche liver inflammatory fibrotic diseases, the company points out.
The VAP-1 antibody program is Phase II ready, according to Biotie. The company is currently optimizing the scale-up of the manufacturing process for BTT-1023 and expects to start proof-of-concept clinical studies in selected indications in the second half of 2012.
Source: http://www.genengnews.com/gen-news-highlights/biotie-regains-asia-pacific-rights-for-vap-1-antibody-program-from-seikagaku/81246672/
Posted under Asia, Drug Development, Press Releases, R & D | Comments Off
MiRagen Pockets $20M to Further miRNA-Based Drugs
Last Updated on Monday, 7 May 2012 04:38 Written by Editor Monday, 7 May 2012 04:37
MiRagen Therapeutics completed a $20 million Series B financing. The company will use the money to advance development of its miRNA-based therapeutics pipeline. The financing is being led by Remeditex with participation from miRagen’s existing investor syndicate, which includes Amgen Ventures, Atlas Venture, Boulder Ventures, and Broadview Ventures.
“In a short period of time, miRagen has delivered significant advances that help to translate new biology into next-generation therapeutic candidates,” notes Bruce Booth, D.Phil., miRagen’s chairman of the board and partner at Atlas Venture. “The team has generated these compelling results in a capital-efficient manner, and we look forward to moving the company to the logical next level with the Series B investment.”
MiRagen’s pipeline is at the preclinical stage. The antimiR program is the most advanced and comprises three candidates. These molecules are aimed at chronic heart failure, post myocardial infarction (MI) remodeling, and polycythemia vera. MiRagen also has one candidate at the lead optimization stage, which is being evaluated in cardiac fibrosis. Additionally, there are four drug compounds in target validation studies against peripheral arterial disease, cardiometabolic disease, vascular disease, and amyotrophic lateral sclerosis.
Additionally, miRagen is coupling its expertise with outside partners. This January it signed an agreement with Silence Therapeutics to evaluate the potential combination of the latter’s DBTC delivery system with its own miRNA-based therapeutics. The chronic heart failure and post-MI remodeling candidates are partnered with Servier. In October 2011, Servier paid $45 million up front for these two drugs as well as a yet to be identified cardiovascular target. If all milestones are reached in all three programs, the deal will total $1 billion to miRagen.
MiRagen is also working with Santaris Pharma in cardiovascular and muscle diseases, using Santaris’ locked nucleic acid drug platform. Additionally, miRagen entered into a collaboration with RXi to evaluate the potential utility of RXi’s rxRNA technology against specific miRNA targets of interest to miRagen in the areas of cardiac and neuromuscular disease.
The company has exclusive rights to the technology and intellectual property related to the in vivo use of discoveries made by the University of Frankfurt and licensed by t2cure regarding miR-92, a regulator of neoangiogenesis as part of ischemic disease. Furthermore the firm has license arrangements for discoveries made at the University of Texas, University of North Carolina, and University of Colorado.
Source: http://www.genengnews.com/gen-news-highlights/miragen-pockets-20m-to-further-mirna-based-drugs/81246671/
Posted under Drug Development, North America, Press Releases, R & D, RNA Reasearch | Comments Off
Novo Nordisk, Kennedy Institute Partner on Rheumatoid Arthritis Drug and Biomarker R&D
Last Updated on Monday, 7 May 2012 04:33 Written by Editor Monday, 7 May 2012 04:33
Novo Nordisk is partnering with Oxford University’s Kennedy Institute of Rheumatology in the U.K. for the discovery and development of new biomarkers and drug targets for rheumatoid arthritis and other inflammatory autoimmune diseases. Under terms of the agreement, Novo Nordisk will fund 10 researchers at the Kennedy Institute to work within the partnership.
The Institute has in the past made key discoveries in the field of rheumatoid arthritis pathobiology, and its head, professor Sir Marc Feldman, M.D., was one of the co-discoverers of anti-TNF as a therapeutic approach to the disease. The translational research center will work in partnership with Novo Nordisk to apply its expertise to the discovery of new treatments.
“As a translational research center, we are keen to do clinical research on truly innovative ideas that have the potential to improve how patients with autoimmune inflammatory disease are treated today,” professor Feldman remarks. “We will work closely together with Novo Nordisk to apply the most advanced translational research approaches available for discovering new mechanisms and validating drug targets and candidates in autoimmune inflammatory disease in a variety of human disease tissue types and at different stages of disease, to ensure comprehensive characterization of each compound’s clinical potential.”
Source: http://www.genengnews.com/gen-news-highlights/novo-nordisk-kennedy-institute-partner-on-rheumatoid-arthritis-drug-and-biomarker-r-d/81246669/
Posted under Drug Development, North America, Press Releases, R & D, Research Projects | Comments Off
Scientists Identify Potential Target for Treating Cocaine Addiction
Last Updated on Monday, 7 May 2012 04:24 Written by Editor Monday, 7 May 2012 04:24
Scientists report new insights into the mechanism by which repeated exposure to cocaine induces addiction. The studies in mice demonstrate that cocaine downregulates the active form of Rac1, a small GTPase known to control actin remodelling, and that this leads to enhanced actin turnover, and increases the density of immature dendritic spines on nucleus accumbens (NAc) neurons in the brain’s key reward center.
The researchers, led by a team at Mount Sinai School of Medicine’s Fishberg Department of Neuroscience and Friedman Brain Institute, showed in mice that overexpression of a dominant negative mutant of Rac1 or local knockout of the native gene was enough to increase the density of immature dendritic spines on the NAc neurons, without cocaine administration. Encouragingly, transiently increasing levels of Rac1 blocked the addiction-causing effects of repeated cocaine use and the accompanying neural changes.
Reporting their findings in Nature Neuroscience, Eric J. Nestler and colleagues suggest their results could help in the design of new treatments for cocaine addiction. Their paper is titled “Rac1 is essential in cocaine-induced structural plasticity of nucleus accumbens neurons.”
“The research gives us new information on how cocaine affects the brain’s reward center and how it could potentially be repaired,” Dr. Nestler says. “This is the first case in the brain in vivo where it’s been possible to control the activity of a protein, inside nerve cells in real time. Our findings reveal new pathways and targets.”
Source: http://www.genengnews.com/gen-news-highlights/scientists-identify-potential-target-for-treating-cocaine-addiction/81246662/
Posted under North America, Press Releases, R & D, Research Projects | Comments Off
Oligomerix Raises $2M for Tau Protease Inhibitor Alzheimer Disease Program
Last Updated on Monday, 7 May 2012 04:22 Written by Editor Monday, 7 May 2012 04:22
Oligomerix raised $2 million in a Series A round of financing to progress its tau protease inhibitor program for treating Alzheimer disease. The financing round comprises both the issue of new convertible preferred shares and debt conversion.
Oligomerix is focused on the development of small molecule drugs and immunotherapeutics that target neurotoxic tau oligomers for the treatment of Alzheimer disease and related neurodegenerative disorders. The tau protease inhibitor program aims to neutralize tau outside of neurons, which the firm says is a more feasible drug discovery approach than targeting intraneuronal tau oligomer formation. The firm has developed a compound screening assay to identify disease-modifying small drugs and antibody-based therapeutics targeting tau oligomers and their proteolytic activity.
“Our research has shown that inhibiting tau oligomer protease may be an effective intervention for not only improving cognitive function, but also interrupting disease progression in Alzheimer disease,” comments James Moe, Ph.D., president and CEO. “Oligomerix’ primary goal is to identify, optimize, and select three to five lead NCEs to enable in vivo studies in a tauopathy mouse model to isolate candidates for IND-enabling studies…Based on our research, the well-characterized reproducible pattern of the initiation and spread of pathological aggregates of tau protein during the progression of Alzheimer disease provides a direct intervention point for tau protein’s mechanism of action, and a druggable target.”
Four of the firm’s product development programs have received grant funding from the NIH, the National Institute of Aging, and the Alzheimer’s Drug Discovery Foundation. In November 2011 Oligomerix was awarded a $1.6 million Phase II Small Business Innovation Research from the NIH to progress its tau-targeting small molecule and antibody programs, both for drug development and biomarker applications.
Source: http://www.genengnews.com/gen-news-highlights/oligomerix-raises-2m-for-tau-protease-inhibitor-alzheimer-disease-program/81246660/
Posted under Drug Development, North America, Press Releases, R & D | Comments Off
Iris Pharma, RxGen Partner on Integrated Ophthalmology Research Services
Last Updated on Monday, 7 May 2012 04:18 Written by Editor Monday, 7 May 2012 04:18
French firm Iris Pharma and RxGen have established an alliance through which they aim to provide fully integrated bench-to-bedside ophthalmology research services to the pharma and biotech industries worldwide. Iris specializes in preclinical and clinical ophthalmic contract research, while U.S.-based RxGen is a preclinical CRO focused on the development and application of translational research models.
Through their new collaboration Iris will be able to offer access to RxGen’s nonhuman primate ophthalmic research models and related preclinical in vivo services, through a flexible model that will allow clients to access both firms’ combined preclinical and clinical expertise and capabilities. Iris says the ability to offer integrated packages of services and a comprehensive suite of preclinical and clinical drug development services will represent a significant benefit for clients.
“The combination of RxGen’s in vivo ophthalmic capabilities in nonhuman primates and Iris Pharma’s world-leading position in ophthalmology positions us to provide superior innovative and adaptive services that will speed time to market for our customers,” comments Christopher Stanley, chief business officer of RxGen.
Source: http://www.genengnews.com/gen-news-highlights/iris-pharma-rxgen-partner-on-integrated-ophthalmology-research-services/81246655/
Posted under Drug Development, Europe, Press Releases, R & D | Comments Off
Humira Anchors Abbott’s 44% Increase in Net Income This Quarter Compared to Q1 2011
Last Updated on Monday, 7 May 2012 04:16 Written by Editor Monday, 7 May 2012 04:16
Abbott Laboratories is reporting a 44% year-over-year leap in net income during the first quarter. The results were propelled by Humira, which has begun its expected march to overtaking Lipitor as the world’s top-selling drug. The strong quarter prompted the company to raise its ongoing earnings-per-share outlook for 2012, during which it plans to spin off its drug development units.
Abbott recorded net income of $1.24 billion on group sales that increased 4.6%, to $9.457 billion. About half, or $4.072 billion, came from its proprietary pharmaceuticals unit. The unit saw sales rise 8.3% over Q1 2011, led by Humira, which racked up $1.934 billion in sales, up 17.4% from the first quarter of 2011. Humira’s sales were almost six times those of Abbott’s next best-selling drug Trilipix/TriCor at $329 million.
Humira is approved for a variety of indications including RA, Crohn disease, and psoriasis, with Abbott studying additional indications for the drug. Abbott has initiated two Phase III trials to evaluate Humira in patients with moderate-to-severe hidradenitis suppurativa, a skin condition for which no treatments have been approved. “Substantial research and development and selling support has been and continues to be dedicated to maximizing the worldwide potential of Humira,” Abbott states.
In that report, Abbott forecasted “low double-digit growth for worldwide Humira sales in 2012.” One likely driver of increased sales for the drug this year is in Europe, where it obtained approval in moderate-to-severe ulcerative colitis in April. The sanction marks the drug’s seventh indication in the EU. Humira is the first and only self-injectable biologic therapy available for UC patients in Europe.
Humira’s 2012 sales are also helped by the absence of patent expirations like those affecting the top-selling drugs of 2011. Last week a consensus of analyst forecasts compiled by Thomson Reuters Pharma projected that neither Pfizer’s anticholesterol drug Lipitor nor blood thinner Plavix, marketed by Sanofi and Bristol-Myers Squibb, will crack the top 10 sales list.
Lipitor’s U.S. patent expired in November, while Q1 2012 is the last full quarter of patent protection for Plavix, which is expected to face several cheaper generic competitors after it goes off patent next month. Last year, Lipitor sales fell $1.156 billion, or 10%, to about $9.6 billion, while Plavix sales were about $9.8 billion after combining $7.087 billion, up 6% from 2010 (BMS), plus €2.04 billion, down 2.1% from ‘10 ($2.679 billion) (Sanofi).
Humira is expected to retain its market-leading position through 2016, though EvaluatePhrama last year lowered its projection to $9.7 billion from $10.1 billion forecast in 2010 by EvaluatePharma. Reuters last week forecast $11.75 billion. All those numbers still fall short, however, of the almost $13 billion achieved by Lipitor at its peak in 2006. And the only condition for which a new $13 million drug is even foreseen in the future is Alzheimer disease, though Reuters has reported that expectations for an effective treatment remain low, despite ongoing late-stage clinical trials of drug candidates from Pfizer, Eli Lilly, and Johnson & Johnson.
In explaining its strong proprietary pharma sales, Abbott also cited several other strong drug franchises including the testosterone replacement gel AndroGel, the digestion aid Creon, the advanced prostate cancer drug Lupron, and the thyroid medicine Synthroid. AndroGel sales zoomed 23.6% in Q1 to $241 million; while sales of Creon rose 10% to $146 million; Synthroid sales increased 9.1% to $155 million; and Lupron, 8%, to $199 million.
The company’s strong start this year has enabled it to raise its EPS forecast for this year, to between $5.00 and $5.10 per share, from between $4.95 and $5.05, according to Miles D. White, Abbott’s chairman and CEO.
The strong Q1 results come as Abbott continues to plan a spinoff of its proprietary pharmaceuticals and biologics into an $18 billion-a-year drug development company to be called AbbVie. Its chairman and CEO will be Richard A. Gonzalez, currently evp, global pharmaceuticals for the current Abbott. The surviving company, which White will run and which will continue to be called Abbott, would focus on diagnostics, devices, nutrition, and branded generics businesses. “We remain focused on the process of separating Abbott into two leading health care companies, which remains on track to be completed by the end of the year,” White remarks.
Source: http://www.genengnews.com/gen-news-highlights/humira-anchors-abbott-s-44-increase-in-net-income-this-quarter-compared-to-q1-2011/81246654/
Posted under Drug Development, Europe, Press Releases | Comments Off
Alder Scores $38M to Be Used for Its Two Clinical-Stage mAb Therapeutics
Last Updated on Monday, 7 May 2012 04:13 Written by Editor Monday, 7 May 2012 04:13
Alder BioPharmaceuticals has closed a $38 million Series D financing round. Proceeds of the financing will support clinical development of mAb therapeutic candidates ALD518 and ALD403. The money will also support preclinical studies including a therapeutic targeting PCSK9 for treating dyslipidemia.
ALD518, an antibody to the pro-inflammatory cytokine IL-6, is currently being investigated in Phase II studies in cancer-related indications, which were retained by the company in its partnership with Bristol-Myers Squibb (BMS) in 2009. BMS is developing the antibody for autoimmune diseases (BMS-945429).
ALD403 is a calcitonin gene-related peptide (CGRP) inhibiting antibody therapeutic for treatment of migraines. Clinical investigation of ALD403 will begin this month, Alder reports. The firm’s PCSK9-targeting mAb, ALD306, is being investigated in cardiovascular patients who have trouble reaching target lipid levels with statins.
“We are proud that in the four years since our Series C round, the Alder team has been tremendously successful in building a pipeline of therapeutics that enabled this round of financing,” says Randall Schatzman, Ph.D., president and CEO. “This financing will provide us with the resources to advance ALD403, which targets well-validated biology in treating migraine and has a similar potential as ALD518 to be a significant game-changer in its disease area.”
Alder explains that its core technology enables the production of antibodies in very high quantities with improved cost structure via their Mab Xpress technology, allowing this class of therapeutics to enter disease areas that have previously been inaccessible for antibodies, such as migraine and cardiovascular disease.
Source: http://www.genengnews.com/gen-news-highlights/alder-scores-38m-to-be-used-for-its-two-clinical-stage-mab-therapeutics/81246653/
Posted under Drug Development, North America, Press Releases | Comments Off
Device sought for early screening
Last Updated on Tuesday, 17 April 2012 05:13 Written by Editor Tuesday, 17 April 2012 05:13
By Carly Harrington
Posted April 15, 2012 at 4 a.m.
Every year when it’s time for her routine physical exam, Nancy Munro’s family practice physician will place electrodes to her chest and run an electrocardiogram to check the health of her heart.
The simple, low-cost EKG test, which records the electrical activity of a person’s heart, takes a matter of seconds and gives her doctor something to look at to determine if there are any problems.
Munro, a retired ORNL researcher, believes a similar method could be used to help primary care doctors detect signs of early Alzheimer’s disease and mild cognitive impairment.
“They only acquire data for 30 seconds, and the doctor can look at it and very quickly decide whether it looks OK or not. That’s the kind of thing we’re aiming for,” she said. “Our goal is to develop a device that can be used in the primary care setting, whether it’s a doctor’s office or a community hospital, that will quickly give a reliable discrimination between normal aging and possibly clinically significant memory problems.”
Munro has been collaborating with fellow scientists at ORNL and the universities of Kentucky and Tennessee to develop an early screening tool using data from an electroencephalogram, or EEG, which measures electrical activity in the brain.
The method was inspired by the work of fellow ORNL researcher Lee Hively, who had developed a way to analyze data, including EEG data, forewarning of epileptic seizures.
“As I got to know more about his research, we discussed the possibility of looking at other brain disorders, and one of the things we discussed was Alzheimer’s,” said Munro, whose mother-in-law had been severely affected by the disease.
The group conducted a pilot project using data collected by the University of Kentucky from three groups of patients — patients with no dementia symptoms, patients diagnosed with mild cognitive impairment and patients diagnosed with early Alzheimer’s.
An analysis done via a collaboration between ORNL and the University of Tennessee showed positive results in distinguishing between the three.
Meanwhile, a working memory test, which could be used in a memory disorders clinic, was added to the study.
When looking at the EEG signals from the different parts of the brain, the mild cognitive impairment group processed the data more like the Alzheimer’s folks did, Munro said.
“They’re showing more activity in a different part of the brain than what the normal pattern is.
“It’s parallel to the Alzheimer’s group, so it shows that there is a difference in how the brain is functioning between the normal and the mild cognitive impairment group,” she added.
The group is now in the process of seeking additional funding to expand its initial study.
Munro said their approach would give a better basis for knowing whether someone should be referred to a specialist or not.
It also could be used in the drug discovery process by providing a low cost way of assessing whether the compounds they’re trying to develop are helpful.
“What we’re trying to do is not aimed at untangling the disease mechanism at all,” she said.
“It’s trying to get at very early changes, just as early as possible so we can identify people and get treatment.”
Get Copyright Permissions © 2012, Knoxville News Sentinel Co.
Want to use this article? Click here for options!
© 2012 Knoxville News Sentinel. All rights reserved.
Source: http://www.knoxnews.com/staff/carly-harrington/
Posted under HT Screening, Nanotechnology, North America, Press Releases, R & D, Research Projects | Comments Off
Newborn Screening for Spinal Muscular Atrophy by Calibrated Short-Amplicon Melt Profiling
Last Updated on Tuesday, 17 April 2012 05:04 Written by Editor Tuesday, 17 April 2012 05:04
Steven F. Dobrowolski1,*,
Ha T. Pham2,
Frances Pouch-Downes3,
Thomas W. Prior4,
Edwin W. Naylor5 and
Kathy J. Swoboda6,7
+ Author Affiliations
1Department of Pathology, Children’s Hospital of Pittsburgh, Pittsburgh, PA;
2ARUP Laboratories, Salt Lake City, UT;
3Michigan Department of Community Health, Lansing, MI;
4Department of Pathology, Ohio State University, Columbus, OH;
5BioChem Genetics LLC, Isle of Palms, SC;
6Departments of Neurology and
7Pediatrics, University of Utah School of Medicine, Salt Lake City, UT.
Abstract
BACKGROUND: The management options for the autosomal recessive neurodegenerative disorder spinal muscular atrophy (SMA) are evolving; however, their efficacy may require presymptom diagnosis and continuous treatment. To identify presymptomatic SMA patients, we created a DNA-based newborn-screening assay to identify the homozygous deletions of the SMN1 (survival of motor neuron 1, telomeric) gene observed in 95%–98% of affected patients.
METHODS: We developed primers that amplify a 52-bp PCR product from homologous regions in the SMN1 and SMN2 (survival of motor neuron 2, centromeric) genes that flank a divergent site at site c.840. Post-PCR high-resolution melt profiling assessed the amplification product, and we used a unique means of melt calibration to normalize profiles. Samples that we had previously characterized for the numbers of SMN1 and SMN2 copies established genotypes associated with particular profiles. The system was evaluated with approximately 1000 purified DNA samples, 100 self-created dried blood spots, and >1200 dried blood spots from newborn-screening tests.
RESULTS: Homozygous deletion of SMN1 exon 7 produced a distinctive melt profile that identified SMA patients. Samples with different numbers of SMN1 and SMN2 copies were resolved by their profiles. All samples with homozygous deletions were unambiguously recognized, and no normal sample was misidentified as a positive.
CONCLUSIONS: This assay has characteristics suitable for population-based screening. A reliable screening test will facilitate the identification of an SMA-affected cohort to receive early intervention to maximize the benefit from treatment. A prospective screening trial will allow the efficacy of treatment options to be assessed, which may justify the inclusion of SMA as a target for population screening.
Received for publication January 21, 2012.
Accepted for publication March 15, 2012.
© 2012 The American Association for Clinical Chemistry
Source: http://www.clinchem.org/content/early/2012/04/09/clinchem.2012.183038.short?rss=1
Posted under HT Screening, North America, Press Releases, Research Projects | Comments Off
Europe plans molecular screening center for translational research
Last Updated on Tuesday, 17 April 2012 04:28 Written by Editor Tuesday, 17 April 2012 04:28
Lucas Laursen
05 April 2012
Almost a decade ago, the US National Institutes of Health kicked off its Molecular Libraries Initiative to provide academic researchers with access to the high-throughput screening tools needed to identify new therapeutic compounds. Europe now seems keen on catching up.
Last month, the Innovative Medicines Initiative (IMI), a €2 billion ($2.6 billion) Brussels-based partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), invited proposals to build a molecular screening facility for drug discovery in Europe that will combine the inquisitiveness of academic scientists with industry know-how. The IMI’s call for tenders says the facility will counter “fragmentation” between these sectors.
The IMI will offer €80 million over five years to the consortium selected to build up and manage a centralized screening infrastructure and a library of up to 500,000 compounds. Expressions of interest from qualified academic-industry partnerships are due in mid-May.
Major pharmaceutical companies have more experience with high-throughput screening than do most academic institutes. Yet companies often limit tests of their closely held candidate chemicals to a fraction of potential disease targets. By pooling chemical libraries and screening against a more diverse set of targets—and identifying more molecular interactions—both academics and pharmaceutical companies stand to gain, says Hugh Laverty, an IMI project manager.
The IMI already has commitments from seven members of the EFPIA to contribute 50,000 compounds each, and future academic partners are expected to donate between 100,000 and 200,000 total. (The NIH similarly has around 300,000 chemically diverse compounds in its small-molecule repository.)
Onlookers note the challenge of handling so many molecular candidates. Whoever manages the IMI’s ‘European Screening Centre’ will need to develop an efficient process for preselecting compounds to make the high-throughput screening worth the cost to taxpayers, says Robert Damoiseaux, scientific director of the Molecular Screening Shared Resource (MSSR) at the University of California–Los Angeles. Damoiseaux recommends that Europeans look across the pond for insight on this: “It’s certainly really useful to compare notes with American researchers and have a look at which lessons can be learned, what paradigms worked and what didn’t.”
Ultimately, a facility as large as the proposed European Screening Center should be more efficient than the smaller sites that already exist around Europe, says Gerardo Turcatti, who directs the Biomolecular Screening Facility at the Swiss Federal Institute of Technology in Lausanne. He adds, however, that sorting out intellectual property in any collaboration that also involves industrial applications will be a challenge.
Laverty says the IMI will help the winning consortium negotiate the particulars with the industry partners. “We’re very aware of intellectual property concerns,” he explains, adding that identifying a promising compound might trigger milestone payments to a compound’s contributor.
Source: http://www.nature.com/nm/journal/v18/n4/full/nm0412-477a.html
Posted under Compound Screening, Europe, Press Releases, R & D, Research Projects | Comments Off
Screen uncovers hidden ingredients of Chinese medicine
Last Updated on Thursday, 12 April 2012 07:08 Written by Editor Thursday, 12 April 2012 07:08
Genetic audit reveals that some traditional remedies contain endangered animals and toxic plants.
Chinese herbal medicines contain ingredients derived from endangered animals, toxic plants and livestock, a genetic audit has discovered. Few of these ingredients were listed on the packaging.
“There’s absolutely no honesty in the labelling of these products. What they declare is completely at odds with what’s in there,” says Mike Bunce, a geneticist at Murdoch University near Perth, Australia, who led the study. The results are published today in PLoS Genetics1.
Many traditional Chinese medicines contain species not listed in the ingredients.
Yang Liu/Corbis
Traditional Chinese medicines rack up billions of dollars in worldwide sales each year, and exports to Western countries are on the rise. However, most of the medicines have not been proved to be effective, and industry regulation is scant.
When the medicines have been ground up, it is very difficult to tell what they are made of. In the past, researchers have examined herbal medicines by running assays for toxic compounds and using DNA tests to determine whether a specific plant or animal is present.
But mislabelling is rampant, so researchers do not always know what to look for and conventional approaches will miss many of the species that are present, says Bunce.
His team turned instead to next-generation DNA sequencers, which can rapidly read thousands of DNA strands. The researchers can then check the genetic sequences against databases to learn which plants or animals they come from. This ‘deep sequencing’ technique has been used to characterize mixtures of microbes living in environments such as oceans and animal guts.
More harm than good
Bunce’s team sequenced DNA from 15 traditional Chinese medicine preparations that had been seized by Australian customs, including powders, tablets and teas. Focusing on DNA from chloroplasts and mitochondria — energy-producing structures in cells that have their own genomes — the researchers produced 49,000 genetic sequences.
They identified 68 families of plants, including a poisonous herb called Ephedra and the woody vine Aristolochia. Sometimes known as birthwort, Aristolochia contains aristolochic acid, which can cause kidney and liver damage and bladder cancer. Medicinal use of the herb probably explains high rates of bladder cancer in Taiwan, according to a paper published this week in Proceedings of the National Academy of Sciences2.
At least one of the four medicines that contained Aristolochia DNA also contained aristolochic acid. Other medicines contained DNA from plants in the same family as ginseng — the root of which is illegal to trade internationally — as well as soya and nut-bearing plants, which can cause severe allergic reactions. But many plant DNA sequences could not be pinned to individual species, because plant genetic databases are incomplete.
Mix and match
The researchers also found DNA from eight genera of vertebrate animals. Genetic material from the critically endangered Saiga antelope (Saiga tatarica) was present in one powder; and boxes marked as bear-bile powder or decorated with the outline of a bear contained traces of DNA from the Asian black bear (Ursus thibetanus), which is classed as vulnerable.
Nearly half of the medicine samples tested for animal DNA contained genetic material from multiple animals, and more than three-quarters included DNA from animals not listed on the packaging, such as water buffalo, domestic cows and goats.
“Many of those traditional Chinese medicine supplements are such adventurous mixtures of multiple ingredients that, quite frankly, nothing surprises me about them,” says Edzard Ernst, chair in complementary medicine at Peninsula Medical School in Exeter, UK.
Bunce thinks that food and drug regulatory agencies should consider adopting deep-sequencing techniques to screen herbal medicines; his team has applied for a grant to test its methods on supplements that are on the market in Australia. The researchers estimate that in their study, each sample cost US$35, excluding labour, to test, but the cost will fall as DNA sequencing technology becomes cheaper.
“Screening might be a way forward,” says Ernst. “It would be surprising if, among these thousands of ingredients, there were not a few that have the potential to do more good than harm. However, my impression is that we are a very long way from instilling proper science into this area such that patients are not at risk of either direct harm or the indirect harm of treating serious conditions with useless supplements.”
Source: http://www.nature.com/news/screen-uncovers-hidden-ingredients-of-chinese-medicine-1.10430
Posted under Natural Products, North America, Press Releases | Comments Off
Drug Safety Executive Council™ to Participate in 8th North American Drug Discovery Workshop: Discovery to IND: De-Risking Drug Discovery Programs Early
Last Updated on Thursday, 12 April 2012 07:01 Written by Editor Thursday, 12 April 2012 07:01
Dr. Ernie Bush, Vice President of Collaborative Projects for DSEC, speaks on industry trends in predictive toxicology
The Drug Safety Executive Council™ (DSEC™) is pleased to announce that Dr. Ernie Bush, Director of Collaborative Projects, is a featured speaker at the 8th North American Drug Discovery Workshop, co-sponsored by Cyprotex. Dr. Bush’s presentation is entitled Industry Trends in Predictive Toxicology Technologies.
The session is sponsored by Cyprotex and its technology partners ChanTest (an ion channel company) and InSphero (a 3-D microtissue company), and will take place on April 12th from 8:30 a.m. to 5:30 p.m. at Le Meridien Cambridge Hotel in Cambridge, Massachusetts. Visit http://www.cyprotex.com for program agenda and registration details.
Dr. Bush’s talk will focus on predictive toxicology technologies, including highlighting the high interest from the pharmaceutical and biotech industry in using High Content Analysis tools and 3D cell culture technologies for predictive toxicology applications, as identified in the DSEC 4th Annual Survey – Technology Adoption in Drug Safety.
Of note, DSEC and Cambridge Healthtech Associates™ (CHA™), through the Technology Evaluation Consortium™ (TEC™), previously brought together 10 major pharmaceutical companies to conduct the initial qualification and validation of CellCiphr™, Cyprotex’s high-content cell health assay technology. The TEC program is designed to ensure new technologies for drug discovery and development are optimized for the pharmaceutical research community.
About DSEC
The Drug Safety Executive Council™ (DSEC™) is an online community focused on the development of better and safer medicines. DSEC is a platform for biopharmaceutical companies, contract research organizations, governmental entities and academic institutions to share knowledge and exchange ideas on improving drug safety assessment. Visit http://www.drugsafetycouncil.org.
DSEC™ is managed by Cambridge Healthtech Associates™ (CHA™), a firm that uses its collaborative model to improve the speed and economics of life science R&D, leveraging its consulting, technology evaluations and communities. Visit http://www.chacorporate.com.
About Cyprotex
Cyprotex was founded in 1999 and headquartered in Macclesfield, UK. With its 2010 acquisition of Apredica, a Watertown, US-based pioneer in predictive toxicology and customised ADME research, Cyprotex now has operations on two continents. Cyprotex has developed proprietary technologies for highly automated in vitro ADME screening (Cloe® Screen), in vitro high content imaging assessment of mechanistic toxicity (CellCiphr™), in silico PBPK modelling (Cloe® PK) for estimating whole-body exposure, and genomic ADME (gADME™) program for defining metabolic pathways and identifying the impact of genetic polymorphisms. Cyprotex’s services take a consultative, collaborative approach that includes custom assay development and emphasizes fast turnaround times. Cyprotex also provides ancillary services through collaborations with partner companies. Cyprotex collaborates with Sygnature Discovery to provide integrated drug discovery services, and with Solvo Biotechnology for drug transporter assays. Over 700 drug, agrochemical, and cosmetic discovery organisations in 31 countries — including large pharmaceutical companies, virtual companies, and academic and not-for-profit organizations — trust Cyprotex for their ADME Tox research needs.
Source: http://www.prweb.com/releases/prwebdrugdiscoveryworkshop/04/prweb9390871.htm
Posted under Drug Development, Education, North America, Press Releases | Comments Off
RiboMed Launches Improved Prognostic Multi Biomarker Epigenetic Test for Brain Cancer
Last Updated on Thursday, 12 April 2012 06:58 Written by Editor Thursday, 12 April 2012 06:58
RiboMed Clinical Services Laboratory (RCSL), a CLIA-certified subsidiary of RiboMed Biotechnologies, today announced the release of a multi-marker methylation prognostic test for grading gliomas, the most common type of brain cancer. The test robustly analyzes 8 genes for differential methylation on FFPE (Formalin Fixed Paraffin Embedded) tumor samples to determine the G-CIMP (Glioma CpG Island Methylation Phenotype) score. The G-CIMP score correlates with patient survival and provides a new tool for physicians as they plan the patient’s treatment. This unique multiple DNA Methylation biomarker test, developed and validated by RCSL and commercialized and marketed by Castle Biosciences, Inc (Friendswood, TX), offers significant improvements in sensitivity, patient sample requirements and reproducibility over the bisulfite DNA methylation platform. These improvements were achieved by utilizing RiboMed’s proprietary and patented bisulfite-free Abscription®-based MethylMeter® platform.
As noted by RiboMed CEO Dr. Michelle Hanna, “The unparalleled sensitivity, accuracy, and reproducibility offered by the Abscription®-based G-CIMP test, coupled with its ability to efficiently assess multiple methylation biomarkers in FFPE patient samples, makes this the best in class option for prognostic glioma testing. Furthermore, MethylMeter is directly applicable to the development of a broad range of new diagnostic, theranostic, and companion diagnostic DNA methylation based assays, particularly those utilizing FFPE samples.” RCSL’s clinical diagnostic assay pipeline includes tests for ovarian and lung cancers.
The G-CIMP biomarker panel was originally discovered and correlated to glioma patient survival by researchers at the MD Anderson Cancer Center (MDACC) and exclusively licensed to Castle Biosciences. After initial unsuccessful attempts at commercialization using traditional bisulfite-based methylation detection platforms, Castle Biosciences adopted RiboMed’s platform based on its ability to assay biomarker DNA Methylation profiles efficiently in degraded DNA found in FFPE patient tumor samples. RiboMed subsequently developed a robust G-CIMP biomarker test that shows concordance with the MDACC clinical DNA Methylation data correlating CIMP Methylation status with patient survival times. RCSL is now performing this test as a service for Castle. Multiple studies have provided ample evidence of clinically significant inter-observer variation of the histological typing and grading of glioma. This variation is clinically significant as treatment plans are based upon grade. The purpose of the G-CIMP biomarker test is to provide objective information to improve grade-related prognosis. “When traditional bisulfite-based technologies were found to be unsuitable for this FFPE assay, RiboMed’s bisulfite-free methylation detection platform effectively circumvented the problems associated with these traditional technologies enabling the rapid development of an accurate and reproducible FFPE glioma tumor assay” stated Castle Biosciences CEO Derek Maetzold. “We are very excited to partner with RiboMed in offering the DecisonDX G-CIMP test since it will significantly improve glioma tumor grading and become the standard of care for these patients.”
About RiboMed: RiboMed Biotechnologies (www.ribomed.com) is a molecular diagnostic company with a focus on Epigenetic Diagnostics and Theranostics in Oncology. The Company develops and provides products, services, and tests for disease screening, diagnostics, theranostics, post-treatment monitoring, and drug development utilizing its proprietary and patented technology platforms for biomarker detection (Abscription®) and methylated DNA isolation and quantification (MethylMagnet® and MethylMeter®). RiboMed Clinical Services Laboratory (RCSL), a fully compliant CLIA certified laboratory subsidiary, offers sensitive and quantitative DNA Methylation profiling clinical assay development services which provide reliable results even with Formalin Fixed Paraffin Embedded tissues.
About Castle: Castle Biosciences is a cancer based molecular diagnostics company whose mission it is to serve individuals afflicted with rare or orphan cancers and those who care for them. The company has commercially available tests for use in eye cancer (uveal melanoma) and brain cancer (glioblastoma). The company’s tests can only be ordered by a licensed physician.
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of RiboMed and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company’s control, and may turn out to be materially different. RiboMed expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.
Source: https://ireach.prnewswire.com/
Posted under DNA Reasearch, Nanotechnology, North America, Press Releases, Research Projects, RNA Reasearch | Comments Off
Main Menu
- Home
- About Bioscreening.net
- Glossary
- Biotechnology Glossary A-I
- Biotechnology Glossary J-Q
- Biotechnology Glossary R-Z
- Bird Flu
- Cheminformatic Glossary
- Endotoxins
- Fullerenes
- Genipin
- Gossypol (Gossipol)
- Grants, Venture Capital, and Government Funding
- High-throughput screening
- Lipinski Rule-of-Five
- Mumie
- Natural Medicine
- Rule-of-Three (Ro3)
- Targeted Libraries
- Web Directory